Second Malignancies in Children Following Treatment for Neuroblastoma

Alberto Garaventa, Bruno De Bernardi

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

On the basis of currently available information, the cumulative incidence of second malignant neoplasm (SMN) for neuroblastoma patients is approximately 2% at 20 years from the initial diagnosis. The most commonly observed SMNs include thyroid carcinomas, osteogenic and soft tissue sarcomas, breast and colon carcinomas, acute myeloid and lymphoid leukemias, Hodgkin's and non-Hodgkin's lymphomas, and brain tumors. Female survivors of neuroblastoma seem to be at higher risk of developing an SMN than males. Other predisposing factors include young age at the time of diagnosis of the first cancer, radiotherapy associated with chemotherapy, high-doses of alkylating agents and administration of topo-isomerase II inhibitors, as well as high cumulative doses and protracted schedules of epipodophyllotoxins. Longer and more targeted surveillance should be recommended including specific cancer screening at younger ages compared to the general population. Risk adapted and response-related regimens should be applied to these patients in an effort to decrease SMNs.

Original languageEnglish
Title of host publicationBrain Metastases from Primary Tumors: Epidemiology, Biology, and Therapy
PublisherElsevier Inc.
Pages61-74
Number of pages14
ISBN (Print)9780128008966
DOIs
Publication statusPublished - Apr 2014

Fingerprint

Second Primary Neoplasms
Neuroblastoma
Podophyllotoxin
Isomerases
Alkylating Agents
Hodgkin Disease
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Early Detection of Cancer
Thyroid Neoplasms
Acute Myeloid Leukemia
Brain Neoplasms
Sarcoma
Causality
Non-Hodgkin's Lymphoma
Survivors
Appointments and Schedules
Colon
Radiotherapy
Breast Neoplasms
Drug Therapy

Keywords

  • Children
  • Genetic aberrations
  • Neuroblastoma
  • Second malignancy
  • Survival
  • Treatment

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Garaventa, A., & De Bernardi, B. (2014). Second Malignancies in Children Following Treatment for Neuroblastoma. In Brain Metastases from Primary Tumors: Epidemiology, Biology, and Therapy (pp. 61-74). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-800896-6.00006-1

Second Malignancies in Children Following Treatment for Neuroblastoma. / Garaventa, Alberto; De Bernardi, Bruno.

Brain Metastases from Primary Tumors: Epidemiology, Biology, and Therapy. Elsevier Inc., 2014. p. 61-74.

Research output: Chapter in Book/Report/Conference proceedingChapter

Garaventa, A & De Bernardi, B 2014, Second Malignancies in Children Following Treatment for Neuroblastoma. in Brain Metastases from Primary Tumors: Epidemiology, Biology, and Therapy. Elsevier Inc., pp. 61-74. https://doi.org/10.1016/B978-0-12-800896-6.00006-1
Garaventa A, De Bernardi B. Second Malignancies in Children Following Treatment for Neuroblastoma. In Brain Metastases from Primary Tumors: Epidemiology, Biology, and Therapy. Elsevier Inc. 2014. p. 61-74 https://doi.org/10.1016/B978-0-12-800896-6.00006-1
Garaventa, Alberto ; De Bernardi, Bruno. / Second Malignancies in Children Following Treatment for Neuroblastoma. Brain Metastases from Primary Tumors: Epidemiology, Biology, and Therapy. Elsevier Inc., 2014. pp. 61-74
@inbook{d6bffa9a50814f89849ad842415b6aa4,
title = "Second Malignancies in Children Following Treatment for Neuroblastoma",
abstract = "On the basis of currently available information, the cumulative incidence of second malignant neoplasm (SMN) for neuroblastoma patients is approximately 2{\%} at 20 years from the initial diagnosis. The most commonly observed SMNs include thyroid carcinomas, osteogenic and soft tissue sarcomas, breast and colon carcinomas, acute myeloid and lymphoid leukemias, Hodgkin's and non-Hodgkin's lymphomas, and brain tumors. Female survivors of neuroblastoma seem to be at higher risk of developing an SMN than males. Other predisposing factors include young age at the time of diagnosis of the first cancer, radiotherapy associated with chemotherapy, high-doses of alkylating agents and administration of topo-isomerase II inhibitors, as well as high cumulative doses and protracted schedules of epipodophyllotoxins. Longer and more targeted surveillance should be recommended including specific cancer screening at younger ages compared to the general population. Risk adapted and response-related regimens should be applied to these patients in an effort to decrease SMNs.",
keywords = "Children, Genetic aberrations, Neuroblastoma, Second malignancy, Survival, Treatment",
author = "Alberto Garaventa and {De Bernardi}, Bruno",
year = "2014",
month = "4",
doi = "10.1016/B978-0-12-800896-6.00006-1",
language = "English",
isbn = "9780128008966",
pages = "61--74",
booktitle = "Brain Metastases from Primary Tumors: Epidemiology, Biology, and Therapy",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Second Malignancies in Children Following Treatment for Neuroblastoma

AU - Garaventa, Alberto

AU - De Bernardi, Bruno

PY - 2014/4

Y1 - 2014/4

N2 - On the basis of currently available information, the cumulative incidence of second malignant neoplasm (SMN) for neuroblastoma patients is approximately 2% at 20 years from the initial diagnosis. The most commonly observed SMNs include thyroid carcinomas, osteogenic and soft tissue sarcomas, breast and colon carcinomas, acute myeloid and lymphoid leukemias, Hodgkin's and non-Hodgkin's lymphomas, and brain tumors. Female survivors of neuroblastoma seem to be at higher risk of developing an SMN than males. Other predisposing factors include young age at the time of diagnosis of the first cancer, radiotherapy associated with chemotherapy, high-doses of alkylating agents and administration of topo-isomerase II inhibitors, as well as high cumulative doses and protracted schedules of epipodophyllotoxins. Longer and more targeted surveillance should be recommended including specific cancer screening at younger ages compared to the general population. Risk adapted and response-related regimens should be applied to these patients in an effort to decrease SMNs.

AB - On the basis of currently available information, the cumulative incidence of second malignant neoplasm (SMN) for neuroblastoma patients is approximately 2% at 20 years from the initial diagnosis. The most commonly observed SMNs include thyroid carcinomas, osteogenic and soft tissue sarcomas, breast and colon carcinomas, acute myeloid and lymphoid leukemias, Hodgkin's and non-Hodgkin's lymphomas, and brain tumors. Female survivors of neuroblastoma seem to be at higher risk of developing an SMN than males. Other predisposing factors include young age at the time of diagnosis of the first cancer, radiotherapy associated with chemotherapy, high-doses of alkylating agents and administration of topo-isomerase II inhibitors, as well as high cumulative doses and protracted schedules of epipodophyllotoxins. Longer and more targeted surveillance should be recommended including specific cancer screening at younger ages compared to the general population. Risk adapted and response-related regimens should be applied to these patients in an effort to decrease SMNs.

KW - Children

KW - Genetic aberrations

KW - Neuroblastoma

KW - Second malignancy

KW - Survival

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84902403450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902403450&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-800896-6.00006-1

DO - 10.1016/B978-0-12-800896-6.00006-1

M3 - Chapter

AN - SCOPUS:84902403450

SN - 9780128008966

SP - 61

EP - 74

BT - Brain Metastases from Primary Tumors: Epidemiology, Biology, and Therapy

PB - Elsevier Inc.

ER -